☆ 4.6 Article

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST) : a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

LANCET RESPIRATORY MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Rheumatology

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

Paul C. Cremer et al.

Summary: The trial evaluating the efficacy of mavrilimumab in COVID-19 patients with systemic hyperinflammation did not show a significant difference in the proportion of patients alive and off oxygen therapy at day 14. Larger trials are needed to further assess the potential benefits or harms of mavrilimumab therapy in this patient population.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genetic mechanisms of critical illness in COVID-19

Erola Pairo-Castineira et al.

Summary: In critically ill patients with COVID-19, host genetic variants associated with antiviral defense mechanisms and inflammatory organ damage were identified through a genome-wide association study. These genetic signals provide potential targets for therapeutic development and repurposing of existing drugs. Large-scale randomized clinical trials will be essential to confirm the effectiveness of targeted treatment strategies.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Clonal expansion and activation of tissue-resident memory-like T(H)17 cells expressing GM-CSF in the lungs of patients with severe COVID-19

Yu Zhao et al.

Summary: Hyperinflammation contributes to lung injury in severe COVID-19, with T-RM 17 cells identified as potential orchestrators of this process. High levels of IL-17A and GM-CSF were associated with a more severe clinical course in patients with COVID-19.

SCIENCE IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

Ryan S. Thwaites et al.

Summary: The study found that levels of inflammatory cytokines and chemokines gradually increased with the severity of COVID-19, with IL-6 and GM-CSF playing central roles in the pathogenesis of the disease. Comparisons with samples from fatal influenza patients revealed that GM-CSF was prominent only in COVID-19, further identifying key factors that characterize and distinguish severe and fatal COVID-19.

SCIENCE IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹

Meeting Abstract Rheumatology

MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION

L. Pupim et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis

Manu Shankar-Hari et al.

Summary: This study identified 27 clinical trials and found that the use of IL-6 antagonists was associated with lower 28-day all-cause mortality in patients hospitalized for COVID-19 compared to usual care or placebo. Different risk effects were observed between tocilizumab and sarilumab, increasing understanding of the treatment with these drugs.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Tonny Veenith et al.

Summary: The CATALYST trial aims to identify novel treatments for COVID-19 patients through immunomodulation to improve outcomes. The trial has been approved by the appropriate ethics committee and will disseminate results through national and international presentations and peer-reviewed publications.

BMJ OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Maximilian Ackermann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Jonas Schulte-Schrepping et al.

CELL (2020)

添加到收藏夹

Article Critical Care Medicine

Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities

Puja Mehta et al.

LANCET RESPIRATORY MEDICINE (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Medicine, General & Internal

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study

Zelalem Temesgen et al.

MAYO CLINIC PROCEEDINGS (2020)

添加到收藏夹

Letter Critical Care Medicine

Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series

Andreas Stallmach et al.

CRITICAL CARE (2020)

添加到收藏夹

Article Rheumatology

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Giacomo De Luca et al.

LANCET RHEUMATOLOGY (2020)

添加到收藏夹

Article Immunology

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Miriam Merad et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹

Article Computer Science, Interdisciplinary Applications

brms: An R Package for Bayesian Multilevel Models Using Stan

Paul-Christian Buerkner

JOURNAL OF STATISTICAL SOFTWARE (2017)

添加到收藏夹

Article Microbiology

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Rudragouda Channappanavar et al.

CELL HOST & MICROBE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis

Luca Piccoli et al.

NATURE COMMUNICATIONS (2015)

添加到收藏夹

Article Immunology

Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

Clare A. Notley et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.